17 recruiting, 11 not yet recruiting, 7 active not recruiting, 4 completed. 27 Phase 2, 16 Phase 1, 5 Phase 3.
Follow Sonrotoclax: new trials by email Literature Review of Sonrotoclax trials Research Report on Sonrotoclax
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 44 | 2027-08-04 | 2026-09-10 |
| Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Tacabrutideg, Sonrotoclax, Obinutuzumab - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 30 | 2027-01-01 | 2026-10-21 |
| A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia Zanubrutinib, Obinutuzumab, Sonrotoclax - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2026-12-31 | 2026-06-30 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Sonrotoclax in Participants With Severe Hepatic Impairment Sonrotoclax - Hepatic Impairment, Healthy Adult Participants | Phase 1 | Not yet recruiting | BeOne Medicines | 12 | 2026-11-01 | 2026-10-20 |
| Sonrotoclax Plus Azacitidine in Patients With MDS-IB2 Sonrotoclax, Azacitidine (AZA) - Myelodysplastic Syndromes, High Risk | Phase 1 / Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 60 | 2026-10-15 | 2026-10-21 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-10-01 | 2026-08-18 |
| A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma Zanubrutinib, Obinutuzumab, Sonrotoclax - Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2026-09-01 | 2026-09-10 |
| Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy Zanubrutinib, Sonrotoclax, CAR-T Cell Therapy - Mantle Cell Lymphoma | Phase 2 | Recruiting | Canadian Cancer Trials Group | 40 | 2026-08-24 | 2026-10-14 |
| Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma Sonrotoclax, Glofitamab, Gemcitabine (1000 mg/m2) - Large B-Cell Lymphoma (LBCL), High-grade B-cell Lymphoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 39 | 2026-08-20 | 2026-08-19 |
| Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification Sonrotoclax, CM336 (BCMA/CD3 bispecific antibody) - Multiple Myeloma (MM) | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2026-08-01 | 2026-07-07 |
| Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL Polatuzumab Vedotin, Rituximab, Cyclophosphamide - Large B-cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 40 | 2026-06-15 | 2026-06-30 |
| Study of SA+X in the Treatment of Newly Diagnosed AML Anthracycline, Ivosidenib, Gilteritinib - Acute Myeloid Leukemia | Phase 2 | Recruiting | Ruijin Hospital | 205 | 2026-05-01 | 2026-07-30 |
| A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia BCL-2 indibitor, Azacitidine (AZA), Blinatumomab - Newly Diagnosed Mixed Phenotype Acute Leukemia | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 52 | 2026-05-01 | 2026-05-07 |
| Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL Zanubrutinib, Sonrotoclax, Computed Tomography - Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 466 | 2026-04-30 | 2026-10-02 |
| Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis sonrotoclax, Daratumumab, Dexamethasone - AL Amyloidosis (AL), t(11;14) Positive | Phase 2 | Recruiting | Peking University People's Hospital | 39 | 2026-02-10 | 2026-07-28 |
| A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia Sonrotoclax, Zanubrutinib, Acalabrutinib - Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | BeOne Medicines | 500 | 2026-01-22 | 2026-09-28 |
| A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults BG-71332, Zanubrutinib, Sonrotoclax - Healthy Volunteers | Phase 1 | Completed | BeOne Medicines | 24 | 2025-09-24 | 2026-04-22 |
| Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 37 | 2025-08-25 | 2026-04-20 |
| A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) Sonrotoclax, Obinutuzumab, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Recruiting | BeOne Medicines | 630 | 2025-06-11 | 2026-10-14 |
| Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2025-06-02 | 2026-04-22 |
Showing 20 of 39. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (14) · Lymphoma, Mantle-Cell (8) · Leukemia, Myeloid, Acute (4) · Lymphoma (4) · Recurrence (3) · Lymphoma, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Multiple Myeloma (2) · Myelodysplastic Syndromes (2) · Neoplasms (2) · Burkitt Lymphoma (1) · Hematologic Neoplasms (1) · Immunoglobulin Light-chain Amyloidosis (1) · Leukemia (1) · Lymphoma, B-Cell, Marginal Zone (1)
BeOne Medicines (15) · BeiGene (4) · City of Hope Medical Center (2) · Fred Hutchinson Cancer Center (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Ruijin Hospital (2) · The First Affiliated Hospital of Soochow University (2) · Alliance for Clinical Trials in Oncology (1) · Canadian Cancer Trials Group (1) · Christine Ryan (1) · German CLL Study Group (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Memorial Sloan Kettering Cancer Center (1) · Peking University People's Hospital (1)
United States (23) · China (21) · Australia (11) · Italy (11) · Germany (10) · Spain (10) · United Kingdom (10) · Brazil (9) · France (9) · New Zealand (7) · Poland (7) · Canada (6) · South Korea (6) · Austria (4) · Argentina (3)
Barbara Eichhorst, Prof. (1) · Christine Ryan, MD (1) · Diego Villa (1) · Geoffrey Shouse (1) · Jacob Soumerai, MD (1) · Jennifer J. Huang, MD, PhD (1) · Jennifer R Brown, MD (1) · Junmin Li (1) · Lu Zhang, M.D. (1) · Lugui Qiu (1) · Mazyar Shadman, MD, MPH (1) · Nitin Jain, MBBS (1) · Robert Puckrin (1) · Suning Chen (1)
PMID 38071379, PMID 40008672, PMID 42385124
2023 (4), P30CA033572 (2), 2025 (1)